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Many transcription coactivators interact with nuclear receptors in a ligand- and C-terminal transactivation
function (AF2)-dependent manner. These include activating signal cointegrator 2 (ASC-2), a recently isolated
transcriptional coactivator molecule, which is amplified in human cancers and stimulates transactivation by
nuclear receptors and numerous other transcription factors. In this report, we show that ASC-2 belongs to a
steady-state complex of approximately 2 MDa (ASC-2 complex [ASCOM]) in HeLa nuclei. ASCOM contains
retinoblastoma-binding protein RBQ-3, /-tubulins, and trithorax group proteins ALR-1, ALR-2, HALR, and
ASH2. In particular, ALR-1/2 and HALR contain a highly conserved 130- to 140-amino-acid motif termed the
SET domain, which was recently implicated in histone H3 lysine-specific methylation activities. Indeed,
recombinant ALR-1, HALR, and immunopurified ASCOM exhibit very weak but specific H3-lysine 4 methyl-
ation activities in vitro, and transactivation by retinoic acid receptor appears to involve ligand-dependent
recruitment of ASCOM and subsequent transient H3-lysine 4 methylation of the promoter region in vivo. Thus,
ASCOM may represent a distinct coactivator complex of nuclear receptors. Further characterization of
ASCOM will lead to a better understanding of how nuclear receptors and other transcription factors mediate
transcriptional activation.
The nuclear receptor superfamily is a group of proteins that
regulate, in a ligand-dependent manner, transcriptional initia-
tion of target genes by binding to specific DNA sequences
named hormone response elements (reviewed in reference 23).
Functional analysis of nuclear receptors has shown that there
are two major activation domains. The N-terminal domain
(AF1) contains a ligand-independent activation function,
whereas the ligand-binding domain (LBD) exhibits ligand-de-
pendent transactivation function (AF2). The AF2 core region,
located at the extreme C terminus of the receptor LBDs, is
conserved among nuclear receptors and undergoes a major
conformational change upon ligand binding (23). This region
has been shown to play a critical role in mediating transacti-
vation by serving as a ligand-dependent interaction interface
with many different coactivators (reviewed in reference 9).
These coactivators, including the p160 family members (i.e.,
SRC-1, SRC-2/GRIP1/TIF2, and SRC-3/ACTR/pCIP/AIB1/
RAC3/TRAM1), CBP/p300, p/CAF, TRAP/DRIP, activating
signal cointegrator 2 (ASC-2), and many others, bridge nuclear
receptors and the basal transcription apparatus and/or re-
model the chromatin structures (9).
Chromatin, the physiological template of all eukaryotic ge-
netic information, undergoes a diverse array of posttransla-
tional modifications that largely impinge on histone amino
termini, thereby regulating access to the underlying DNA (re-
viewed in reference 12). SRC-1 and the p160 family member
ACTR, along with CBP and p300, were recently shown to
contain histone acetyltransferase (HAT) activities and associ-
ate with yet another HAT protein, p/CAF (9). In contrast,
SMRT and N-CoR, nuclear receptor corepressors, form com-
plexes with Sin3 and histone deacetylase proteins (9). These
results are consistent with the notion that the acetylation of
histones destabilizes nucleosomes and relieves transcriptional
repression by allowing transcription factors to access recogni-
tion elements, whereas deacetylation of the histones stabilizes
the repressed state. More recently, the histone arginine meth-
yltransferases CARM1 and PRMT1 were newly defined as tran-
scriptional coactivators of nuclear receptors (4, 40). NSD1 and
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RIZ1, two additional coregulatory proteins with the SET do-
main known to methylate histones (6, 16, 26, 28, 33, 35, 42, 46),
were also reported (10, 50). Likewise, one can expect to iden-
tify additional coactivator molecules with other histone-modi-
fying activities such as lysine methylation, ubiquitination, and
phosphorylation. These distinct histone amino-terminal modifica-
tions can generate synergistic or antagonistic interaction affinities
for chromatin-associated proteins in a combinatorial manner,
which in turn dictates dynamic transitions between transcrip-
tionally active or transcriptionally silent chromatin states (12).
A distinctive structural feature of the AF2-dependent coac-
tivators is the presence of LXXLL signature motifs (i.e., nu-
clear receptor [NR] box) (9). The AF2 core region (helix 12),
upon undergoing a major restructuring upon ligand binding,
forms part of a charged clamp that accommodates coactivators
within a hydrophobic cleft of the receptor LBD, through direct
contacts with these NR boxes (9). Interestingly, the N-CoR/
SMRT nuclear receptor interaction motifs exhibit a consensus
sequence of I/LXXI/HI (i.e., CoRNR box, in which H indicates
hydrophobic residues) (9), which interacts with specific resi-
dues in the same receptor pocket required for coactivator
binding. Thus, discrimination of the subtle differences between
the coactivator and corepressor interaction helices by the nu-
clear receptor AF2 core may provide the molecular basis for
the exchange of coactivators for corepressors, with ligand-de-
pendent formation of the charged clamp that stabilizes NR box
binding and inhibits interaction with the CoRNR box helix.
ASC-2, also named AIB3, TRBP, TRAP250, NRC, and
PRIP, is a novel coactivator gene amplified and overexpressed
in certain human cancers (3, 8, 14, 17, 18, 19, 22, 52). Inter-
estingly, ASC-2 contains two NR boxes. The C-terminal NR
box specifically interacts with liver X receptors, and the N-
terminal box binds many different nuclear receptors, including
retinoic acid receptor (RAR) (19). Transgenic mice overex-
pressing ASC-2 fragment DN1 (ASC-2 residues 849 to 929,
containing the N-terminal motif) but not DN1/m, in which the
LXXLL sequences were mutated to LXXAA to disable the
receptor bindings, were significantly impaired for many signal-
ing pathways mediated by RAR and other receptors, in which
DN1 competitively blocked the interaction of these receptors
with the full-length endogenous ASC-2 (13a). In addition, sin-
gle-cell microinjection of neutralizing antibodies against
ASC-2 abolished transactivation by RAR and other nuclear
receptors that interact with ASC-2 (17; our unpublished re-
sults). Taken together, ASC-2 might be a coactivator molecule
crucial for the function of many different nuclear receptors in
vivo.
Transcriptional coactivators often exist in steady-state com-
plexes in vivo (9). In this study, we found that ASC-2 also
belongs to a steady-state complex of approximately 2 MDa
(ASC-2 complex [ASCOM]) in HeLa nuclei. Our results sug-
gest that ASCOM may represent a new coactivator complex of
nuclear receptors, which is distinct from the previously defined
Swi/Snf, TRAP/DRIP, and SRC-1/CBP complexes (9, 49).
MATERIALS AND METHODS
Plasmids. Vectors encoding glutathione S-transferase (GST) fusion proteins
to histones H2A, H2B, H3, H4, and various H3 point mutants were kind gifts of
Yoichi Shinkai (Kyoto University, Kyoto, Japan). PCR fragments encoding
HALR residues 3712 to 4025 (i.e., HR/SET2), HALR residues 3507 to 4025 (i.e.,
HR/SET1), HR/SET1m1 and HR/SET1 (which are identical to HR/SET1 ex-
cept for the deletion of four residues or the point mutation of a well-conserved
glycine to serine in the SET domain), and the ASC-2 fragments DN1 and DN1/m
were cloned into EcoRI and XhoI restriction sites of the GST fusion vector
pGEX4T (Pharmacia) and pcDNA3 (Invitrogen), respectively. The mammalian
expression vector for RAR, the transfection indicator construct pActin--gal,
and the reporter construct -RARE-LUC were as previously described (17).
Purification of ASCOM. HeLa nuclear extract (1.5 g of protein) was loaded
onto a HiTrap heparin column (3 by 5 ml; Pharmacia) equilibrated with G-150
buffer (20 mM HEPES-KOH [pH 7.9], 0.5 mM EDTA, 0.05% NP-40, 10%
glycerol, 1 mM dithiothreitol [DTT], protease inhibitors, 150 mM KCl). The
bound proteins were eluted with 75 ml of a linear salt gradient (150 to 600 mM
KCl in G buffer). The fractions immunoreactive with anti-ASC-2 were pooled
(350 mM KCl) and dialyzed in Q-80 buffer (20 mM Tris-HCl [pH 7.8], 0.5 mM
EDTA, 20% glycerol, 1 mM DTT, protease inhibitors, 80 mM KCl) for 2 h. The
samples were loaded onto a HiTrap Q column (2 by 5 ml; Pharmacia) equili-
brated with Q-100 (20 mM Tris-HCl [pH 7.8], 0.5 mM EDTA, 20% glycerol, 1
mM DTT, protease inhibitors, 100 mM KCl), and the bound proteins were
eluted with 50 ml of a salt gradient from 100 to 500 mM KCl in Q buffer. The
ASC-2-containing fractions were pooled (300 mM KCl, 20 mg of protein), ap-
plied to a Mono Q column (HR5/5; Pharmacia), and developed with 10 ml of a
salt gradient from 120 to 800 mM KCl. Immunoreactive fractions eluting at 300
mM KCl were pooled and mixed with 60 l of protein G-agarose conjugated with
the previously defined anti-ASC-2 monoclonal antibody (A3C1) (18) at 4°C for
12 h. The beads were recovered and washed three times with 1 ml of IP-300
buffer (20 mM Tris-HCl [pH 7.8], 0.1 mM EDTA, 0.2% NP-40, 10% glycerol, 1
mM DTT, protease inhibitors, 300 mM potassium acetate) and finally washed
with 500 l of phosphate-buffered saline. Bound proteins were eluted twice with
100 l of 100 mM glycine (pH 3.0), precipitated with 10% trichloroacetate, and
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) for matrix-assisted laser desorption ionization–time of flight (MALDI-
TOF) analysis.
Antibodies. Anti-ASC-2 monoclonal antibody (A3C1) and anti-human Med6
(anti-hMed6) polyclonal antibody from rats were as previously described (18,
20). Antibodies against CBP, SRC-2, BRG1, TRAP220, hemagglutinin (HA),
-tubulin, and -tubulin were purchased from Santa Cruz and Boehringer Mann-
heim. Monoclonal antibody against SRC-1 and polyclonal antibody against meth-
ylated K4 of H3 were kind gifts from Dean Edwards and Tony Kouzarides,
respectively. Anti-ASH2, anti-RBQ-3, and anti-HALR antisera were generated
in rats by using, as an antigen, a recombinant ASH2 fragment (ASH2 residues
516 to 624), RBQ-3, or an HALR fragment (HALR residues 2412 to 2886)
expressed in Escherichiacoli. Antisera recognizing both ALR-1 and ALR-2 were
generated in rabbits against a synthetic peptide, MSPPPEESPMSP, derived from
ALR-1 residues 581 to 592 and ALR-2 residues 1 to 12. Each antibody was
affinity purified with recombinant proteins expressed in E. coli and rigorously
tested for the specificity. Antibody coupling to protein G-agarose and immuno-
precipitation were executed as previously described (20).
Transfections and immunofluorescence microscopy. HeLa and CV-1 cells
were grown in 24-well plates with medium supplemented with 10% fetal calf
serum for 24 h and transfected with 100 ng of lacZ expression vector pRSV--gal
and 100 ng of -RARE-LUC reporter gene along with the indicated amounts of
mammalian expression vectors for DN1 and DN1/m. Total amounts of the
expression vectors were kept constant by adding pcDNA3. Transfections and
luciferase assays were done as described previously (17), and the results were
normalized to those of the lacZ expression vector. Similar results were obtained
in more than two similar experiments. Immunofluorescence microscopy was
done essentially as described previously (45). MCF7 cells were incubated with
anti-ASC-2 monoclonal antibody (A3C1) and rabbit polyclonal antibodies
against - or -tubulin. Cells were labeled with fluorescein isothiocyanate-con-
jugated goat anti-mouse and tetramethyl rhodamine isothiocyanate-conjugated
goat anti-rabbit antibodies (Sigma). Coverslips were mounted on glass slides and
examined with an Olympus Fluoview 300 laser scanning confocal microscope.
GST pull-down assays. GST fusions or GST alone was expressed in E. coli,
bound to glutathione-Sepharose 4B beads (Pharmacia) in binding buffer (25 mM
HEPES [pH 7.8], 0.2 mM EDTA, 20% glycerol, 100 mM KCl, and 0.1% NP-40),
and incubated with labeled proteins expressed by in vitro translation by using the
TNT coupled transcription-translation system, with conditions as described by
the manufacturer (Promega, Madison, Wis.). Specifically bound proteins were
eluted from beads with 40 mM reduced glutathione in 50 mM Tris (pH 8.0) and
analyzed by SDS-PAGE and autoradiography as described previously (17).
ChIP. 293T cells were grown in 10-cm-diameter dishes with medium supple-
mented with 10% fetal bovine serum for 24 h and transfected with the indicated
amounts of mammalian expression vectors for RAR, DN1, and DN1/m. The
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total amounts of the expression vectors were kept constant by adding pcDNA3.
Chromatin immunoprecipitation (ChIP) assays were essentially done as de-
scribed previously (51). The primers used were 5-AAGCTCTGTGAGAATCC
TG-3 and 5-GGATCCTACCCCGACGGTG-3, which encompass the
-RARE region and generate a 288-bp PCR fragment. The primers used for the
RARE region of the p21WAF1 promoter were 5-AGACTCTGAGCAGCCTG
AG-3 and 5-AACCCTCATTTGCAGATGGT-3, which generate a 258-bp
PCR fragment.
Histone methyltransferase assays. Immunoprecipitates of ASCOM-contain-
ing HiTrap Q fractions with anti-ASC-2, anti-ASH2, or anti-ALR antibodies or
10 g of GST fusion proteins to HALR and ALR was incubated with 5 g of the
appropriate H3 peptides, purified H2A, H2B, H3, and H4, or calf thymus his-
tones (Roche, Inc.) along with 0.55 Ci of [3H]AdoMet in methyltransferase
buffer (50 mM Tris [pH 8.0], 1 mM phenylmethylsulfonyl fluoride, and 0.5 mM
DTT [final concentration]) for 1 h at 30°C in a final volume of 25 l that was
spotted on Whatman P-81 and then used for scintillation counting, as described
previously (33, 42). The wild-type H3 N-terminal peptide contains residues 1 to
20 of human histone H3 (ARTKQTARKSTGGKAPRKQL-C). In mutant pep-
tides, K4, K9, K14, or K18 was changed to arginine.
RESULTS
ASC-2 exists within a steady-state complex. In HeLa nuclei,
the 250-kDa protein ASC-2 was not observed as a free form
and always existed as a significantly larger steady-state com-
plex. To purify this complex (termed ASCOM for the ASC-2
complex), we subjected HeLa nuclear extract to a series of
biochemical fractionations and immunoaffinity purification
with anti-ASC-2 antibody, as shown in Fig. 1A. The final im-
munoaffinity purification produced many distinct protein
bands (Fig. 1B). Among these, at least eight bands were re-
producibly coimmunoprecipitated by anti-ASC-2 antibody
throughout the purification procedures and were not present
in a control immunoaffinity purification with anti-HA or anti-
ASC-1 antibody (data not shown). MALDI-TOF mass spec-
trometry analyses identified these bands as Trx/ALL-1/MLL-
related protein ALR-1 (MLL2) (GenBank accession no.
2358285, 578 kDa) and its splicing isoform ALR-2 (accession
no. 2358287, 545 kDa) (32), ALR-like protein HALR (MLL3)
(accession no. 10568112, 442 kDa) (43), ASC-2 (accession no.
AAF13595, 250 kDa), ASH2 (accession no. 4009336, 77 kDa)
(11), retinoblastoma binding protein RBQ-3 (accession no.
755750, 66 kDa) (36), -tubulin (accession no. 4929134, 50.1
kDa), and -tubulin (accession no. 13623683, 48.8 kDa).
ALR-1 and ALR-2 differ only in their N termini (32). The
composition of ASCOM was completely distinct from those of
other reported coactivator complexes such as CBP/SRC-1/
SRC-2, CBP/SRC-2/SRC-3/IKK (49), CBP/dTRX in Dros-
ophilamelanogaster (31), p/CAF, and hMediator (9). Consis-
tently, ASCOM behaved differently from complexes containing
CBP, SRC-1, and hMed6 throughout the whole purification
process (Fig. 2A). One obvious exception was that SRC-1 and
a minor peak of CBP appeared to partly comigrate with ASC-2
in the HiTrap Q column fractionations (Fig. 2A, fractions 40 to
44). However, both SRC-1 and CBP were not coimmunopre-
cipitated by anti-ASC-2 antibody in these fractions (Fig. 2B).
Given the fact that SRC-1 and SRC-2 can coexist in the SRC-1
complex (49), we tested whether SRC-2 is also present in these
HiTrap Q fractions. As shown in Fig. 2B, SRC-2 indeed existed
in these fractions but did not associate with ASC-2, like SRC-1.
Taken together, we concluded that ASC-2 is tightly associated
with a series of distinct proteins in vivo within a novel steady-
state complex.
Verification of the ASCOM components. To confirm the
authenticity of the identified proteins as genuine constituents
of ASCOM, we raised specific polyclonal antibodies against
either synthetic or recombinant proteins derived from cognate
cDNAs isolated from various cDNA libraries. Importantly,
these antibodies specifically recognized each cognate band
from HiTrap Q fractions 40 to 44 containing ASC-2/ASCOM
but not from unrelated fractions (30 to 34) (Fig. 2C). From the
ASCOM-containing HiTrap Q fractions (40 to 44), anti-
HALR antibody coimmunoprecipitated ASC-2 (Fig. 2D). Sim-
ilarly, antibodies against ASC-2, ALR, HALR, and ASH2 spe-
cifically coimmunoprecipitated ALR, ASC-2, ASH2, and
RBQ-3 (Fig. 2E and F). In contrast, anti-HA and BRG1 an-
tibodies did not coimmunoprecipitate any of these proteins,
although these antibodies successfully depleted ectopically ex-
pressed HA-tagged proteins or BRG1 from HeLa cells (Fig.
2D, E, and F and data not shown). These results clearly dem-
onstrate that ALR-1/2, HALR, ASH2, and RBQ-3 are genuine
components of ASCOM.
Presence of /-tubulins in ASCOM. Surprisingly, /-tu-
bulins were readily coimmunoprecipitated by anti-HALR an-
tibody and less efficiently coimmunoprecipitated by ASH2 an-
tibody from ASCOM-containing HiTrap Q fractions (Fig. 2F).
Although the presence of nuclear tubulins was previously re-
ported (2, 45), these proteins have not been shown to associate
with any defined nuclear protein. Thus, we further explored
this issue with more-highly purified ASCOM fractions. For
this, HiTrapQ fractions containing ASCOM (fractions 40 to
44) were loaded onto a Mono S column, and anti-ASC-2-
immunoreactive fractions were pooled. These fractions were
then applied to a Superose 6 column and analyzed by immu-
noblotting, as summarized in Fig. 1A. In this Superose 6 gel
FIG. 1. Purification of ASCOM. (A) The chromatography scheme
for the purification of ASCOM from nuclear extract (HeLa NE) is
shown. Numbers and parentheses indicate KCl molarity and pools,
respectively. ASC-2, anti-ASC-2. (B) Mass spectrometric identifica-
tion of polypeptides. Anti-ASC-2 antibody column eluates were run on
an SDS–12% PAGE gel, silver stained, and analyzed by MALDI-TOF,
with gene products and molecular masses (in parentheses) shown on
the right. The masses of the marker proteins (M) are shown on the left,
and asterisks indicate nonspecific bands. Antibody raised against
AC22148, a protein of unknown function, revealed that it is a nonspe-
cific contaminant. MALDI-TOF mass spectrometry analyses failed to
unravel the identity of a protein of approximately 116 kDa (indicated
Unknown).
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filtration column, /-tubulins were copurified with HALR,
ASC-2, ASH2, and RBQ-3, as an approximately 2-MDa com-
plex (Fig. 3A). From Superose 6 fraction 9 containing the
2-MDa complex ASCOM, anti-ASH2 antibody coimmunopre-
cipitated not only ASC-2 and RBQ-3 but also /-tubulins
(Fig. 3B). Although the amount of these nuclear /-tubulins
associated with ASCOM is just a minor fraction of the whole-
cell /-tubulins, antisera against - and -tubulins coimmu-
noprecipitated a detectable amount of ASC-2 from unfraction-
ated whole-cell extracts (data not shown). Consistent with
these results and a recent report (45), indirect immunofluores-
cence microscopy revealed the presence of tubulin in the nuclei
of MCF7 cells (Fig. 3D). While /-tubulins were detected in
both the cytoplasm and the nucleus, ASC-2 was mostly de-
tected in the nucleus. Strongly supporting our biochemical
analyses, at least some of these nuclear /-tubulins colocal-
ized with ASC-2 in the nucleus, as demonstrated with confocal
microscopy (Fig. 3D). In contrast, the nuclear protein BRCA1
was minimally colocalized with ASC-2. These results suggest
that /-tubulins are genuine components of ASCOM. Impor-
tantly, the presence of /-tubulins raises an intriguing possi-
FIG. 2. Confirmation of the identity of the components of AS-
COM. (A) HiTrap Q column fractions subjected to Western analysis
with the indicated antibodies against ASC-2, CBP, SRC-1, and hMed6.
FT, flowthrough; fr#, fraction number. (B) HiTrap Q fractions 40 to
44 were pooled and immunoprecipitated (IP) with anti-ASC-2
(ASC-2) antibody and Western (W) analyzed with the indicated
antibodies. CBP, anti-CBP; SRC-1, anti-SRC-1; SRC-2, anti-
SRC-2. (C) Antibodies were generated against synthetic or recombi-
nant polypeptides encoded by cDNAs isolated based on the MALDI-
TOF mass spectrometry data of the purified proteins.  and ,
HiTrap Q fractions containing ASCOM from HeLa nuclear extract
(fractions 40 to 44) and unrelated fractions (30 to 34), respectively.
Each antibody recognized a protein with the expected molecular
weight (MW) (in thousands). ALR, anti-ALR; HALR, anti-HALR;
ASH2, anti-ASH2; RBQ-3, anti-RBQ-3. (D, E, and F) HiTrap Q
fractions of HeLa nuclear extract containing ASCOM (fractions 40 to
44) were immunoprecipitated with the indicated antibodies (IP), sep-
arated by SDS–4 to 6.5% PAGE, and probed with the indicated anti-
bodies (W). HA, anti-HA; BRG1, anti-BRG1. S and s indicate
supernatant, and P and p indicate precipitate. Ten percent of the total
reaction mixture was loaded as input.
FIG. 3. /-Tubulins in ASCOM. (A) For the size fractionation of
ASCOM, HiTrapQ fractions 40 to 44 (shown in Fig. 2A) were loaded
onto a Mono S column (HR5/5; Pharmacia). Immunoreactive fractions
were pooled, applied to a Superose 6 column (HR10/30; Pharmacia),
and analyzed by immunoblotting as indicated. fr#, fraction number;
W, Western analysis; HALR, anti-HALR; ASC-2, anti-ASC-2;
ASH2, anti-ASH2; RBQ-3, anti-RBQ-3. (B and C) Superose 6
fraction 9 (B) or 28 (C) containing ASCOM or a smaller complex of
approximately 500 kDa was immunoprecipitated with the indicated
antibodies (IP), separated by SDS–4 to 6.5% PAGE, and probed with
indicated antibodies (W). S and P indicate supernatant and precipitate,
respectively. Ten percent of the total reaction mixture was loaded as
input. PIPKI, anti-PIPKI. (D) Cells were treated with -tubulin,
BRCA1, and ASC-2 antibodies. Fluorescein isothiocyanate (green)-
and tetramethyl rhodamine isothiocyanate (red)-conjugated antibod-
ies were used to detect ASC-2 and -tubulin/BRCA1, respectively.
Note the colocalization of ASC-2 and -tubulin. Similar results were
also obtained with -tubulin antibody (data not shown). DIC, differ-
ential interference contrast.
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bility that ASCOM may directly associate with the nuclear
matrix (5). The biological significance of these findings needs
to be further investigated.
Interestingly, RBQ-3 and ASH2 eluted as another distinct
complex of approximately 500 kDa in the Superose 6 sizing
column (Fig. 3A). Within this Superose 6 fraction (no. 28),
anti-ASH2 antibody coimmunoprecipitated ASH2 and RBQ-3
but not the unrelated protein type I- phosphatidylinositol
4-phosphate 5-kinase (Fig. 3C). We noted that this novel com-
plex is similar in size to the previously reported Drosophila
ASH2 complex (30). However, it could simply represent a
submodule of ASCOM, relatively loosely attached to the pu-
tative core ASCOM module.
Notably, ALR-1, ALR-2, HALR, and ASH2 are mammalian
homologues of the Drosophila trithorax group (Trx-G) proteins
(reviewed in reference 7). Thus, we concluded that ASC-2 is a
component of a novel nuclear steady-state complex containing
RBQ-3, a subset of Trx-G proteins, and at least a subpopula-
tion of nuclear /-tubulins.
H3-K4 methylase activity of ASCOM. Trx-G and Polycomb
group (Pc-G) proteins (7), positive and negative effectors of
gene expression, are responsible for the maintenance of tran-
scriptional regulation and provide a cellular memory mecha-
nism throughout development. Some Trx-G and Pc-G proteins
contain a 130- to 140-amino-acid motif termed the SET do-
main, found in a variety of chromatin-associated proteins (7).
Notably, ALR-1/2 and HALR contain the SET domain at their
C termini along with other known protein motifs (Fig. 4A).
Interestingly, agarose beads coupled to histones but not to
oligo(A) retained ASC-2 from ASCOM-containing HiTrap Q
fractions 42 to 44 (Fig. 5A). These results suggest that ASC-2
or ASCOM interacts with histones. Recently, the SET domain
of Drosophila Trx (dTrx) was demonstrated to specifically bind
to H3 (13). Likewise, radiolabeled HR/SET1 (i.e., HALR res-
idues 3507 to 4025) interacted with GST fusions to H3 but not
to H2A, H2B, and H4 (Fig. 5B). These results imply that the
interactions between ASC-2 and histones observed in the ex-
periment for which data is shown in Fig. 5A may have resulted
from direct bindings of the SET domains of HALR/ALR with
H3.
Recently, several SET proteins, such as Schizosaccharomyces
pombe Clr4 as well as hSUV39 h1 and mouse Suv39 h1
(mSuv39 h1), were demonstrated to methylate K9 of histone
H3 (33). This resulted in a binding site for HP1 proteins, a
family of heterochromatic adaptor molecules implicated in
both gene silencing and the higher-order structure of chroma-
tin (16, 27). Another SET protein, G9a, methylated H3-K9 and
K27 (42). Interestingly, anti-ASH2, -ALR, and -ASC-2 anti-
bodies precipitated weak H3 methyltransferase activities from
HiTrap Q fractions 40 to 44 containing ASCOM (Fig. 5C). In
contrast, these immunoprecipitates did not show any methyl-
ase activities toward bovine serum albumin or H4. These H3-
specific methylase activities likely derive from the SET
domains of HALR and/or ALR-1/2, as demonstrated with
GST-HR/SET1 and GST-ALR/SET (Fig. 6A and data not
shown). The involvement of the SET domain was confirmed, as
FIG. 4. HALR/ALR SET domains. (A) Schematic representation of ySET1, hTrx/ALL-1, hHALR, and hALR-1. Various known protein motifs
are color coded as indicated. (B) Amino acid alignment of SET and post-SET domains of hHALR, hALR, dTrx (accession no. AAF55041), ySET1
(accession no. AAB68867), S. pombe Clr4 (accession no. 060016), hG9a (accession no. S30385), and hSUV39 h1 (accession no. NP_003164).
Amino acids conserved among all seven proteins; in hHALR, hALR, dTrx, and ySET1; and in yClr4, hG9a, and hSUV39 h1 are highlighted in red,
green, and blue, respectively. Dashes indicate gaps in the alignment. The red and blue lines mark the extent of the SET and post-SET domains,
respectively. The conserved block of four residues deleted in HR/SET1 is boxed, and the conserved glycine mutated to serine in HR/SET1m1
is marked with an asterisk.
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deletion of a highly conserved 4-amino-acid motif (i.e., GST-
HR/SET1) abolished the methylase activity (Fig. 6A). Inter-
estingly, GST fusion to HALR residues 3708 to 4025 (i.e.,
GST-HR/SET2 in Fig. 6A) had no detectable activities, sug-
gesting that HALR residues 3507 to 3712, encompassing a
PHD finger, could be important for methylase activity.
Whether this region facilitates folding of the SET domain to
accommodate histone tails or directly mediates the enzymatic
reaction warrants further investigation.
Interestingly, the SET domain sequences of ALR-1/2 and
HALR are more homologous to those of dTrx and yeast SET1
(ySET1) than hSUV39 h1, G9a, and Clr4 (Fig. 4B). In addi-
tion, ALR-1/2, HALR, dTrx, and ySET1 do not contain the
cysteine-rich pre-SET domain present in hSUV39 h1, G9a, and
Clr4 (33, 42). Corroborating these differences, GST-HR/SET1-
methylated H3 peptides mutated to arginine at K9, K14, and
K18 but not at K4, although these mutations did not affect the
H3 bindings (Fig. 6B). Thus, the H3 methylation site mediated
by ASCOM in vivo is likely to be K4, although a direct dem-
onstration in vitro (e.g., by Edman degradation) was difficult
due to the very weak H3 methylation activities of HALR/ALR.
Although it is currently unclear how ASCOM-mediated H3-K4
methylation may ultimately lead to local gene activation, we
concluded that ALR-1/2 and HALR are enzymes capable of
methylating H3-K4.
Recruitment of ASCOM to RAR in vivo. The previously
described ligand-dependent protein-protein interactions be-
tween target nuclear receptors and the ASC-2 NR box (14, 19,
22) are believed to mediate the recruitment of ASCOM to
receptors in vivo. Consistent with this expectation, the ASC-2
fragment containing the N-terminal LXXLL motif (i.e., DN1),
but not DN1/m, in which the LXXLL motif was mutated to
LXXAA to disable the receptor interactions, strongly re-
pressed the ligand-dependent transactivation mediated by
RAR in transient cotransfections, whereas the basal level of
transcription was not affected (Fig. 7A). In ChIP assays, DN1,
but not DN1/m, abolished the ligand-dependent recruitment of
ASC-2 to the retinoid-responsive -RARE promoter region
(Fig. 7B, left panel). Importantly, DN1 specifically blocked
endogenous ASC-2 to bind RAR in vivo without affecting the
ligand-dependent recruitment of other LXXLL-based coacti-
vators such as SRC-1 and TRAP220 (Fig. 7B, right panel).
Thus, DN1 and its mutant version DN1/m are excellent tools to
study the role of ASC-2 in nuclear receptor transactivation in
vivo without the complication from other LXXLL-containing
coactivators, although the basis for this specificity is not en-
tirely clear. Nonetheless, our results demonstrate that the in-
hibitory effect of DN1 involves competitive, specific replace-
ment of the endogenous full-length ASC-2 from the binding
receptor. Interestingly, DN1 impaired ligand-dependent re-
cruitment of not only ASC-2 but also other ASCOM compo-
nents (ASH2 and ALR) to the retinoid-responsive -RARE
promoter region in vivo (Fig. 7B, left panel). These results are
consistent with the biochemical studies which indicate that
ASC-2 may only exist within a complex in vivo.
Interestingly, retinoid-induced recruitment of ASC-2/AS-
COM to -RARE was time dependent, with a peak at 20 min
after retinoid treatment, which was nicely correlated with ret-
inoid-dependent H3-K4 methylation of the -RARE promoter
region (Fig. 7C, left panel). ASCOM could be responsible for
this methylation as DN1, but not DN1/m, was inhibitory to the
retinoid-induced ASCOM recruitment as well as H3-K4 meth-
ylation of the -RARE promoter region. Similar results were
also obtained with the retinoid-inducible p21WAF1 promoter
FIG. 5. H3 binding and methylation by ASCOM. (A) HiTrap Q
column fractions containing ASCOM (fractions 40 to 44 in Fig. 2A)
were incubated with either agarose beads coupled to histones or oli-
go(A) (Sigma), separated by SDS–7% PAGE, and probed with anti-
ASC-2 (ASC-2) antibody (W). s and p indicate supernatant and
precipitate, respectively. Ten percent of the total reaction mixture was
loaded as input. (B) The GST pull-down experiments were done as
previously described (17, 19) with GST alone or GST fusions to H2A,
H2B, H3, and H4, and 20% of the total reaction mixture was loaded as
input. (C) HiTrap Q column fractions containing ASCOM (fractions
40 to 44) were immunoprecipitated with the indicated antibodies and
measured for methylation activities with bovine serum albumin, H3, or
H4. HA, anti-HA; ALR, anti-ALR; ASH2, anti-ASH2.
FIG. 6. H3-K4-specific methylation by HALR. (A) Schematic rep-
resentation of HALR and three C-terminal deletion fragments of
HALR with four PHD fingers, an HMG-like domain, and the C-
terminal SET domain. Histone methyltransferase activity was assayed
by incubation of free histones in the presence of S-adenosyl-L-[methyl-
3H]methionine, and incorporated radioactivity was determined by fil-
ter binding. (B) Histone methyltransferase activity was assayed by
incubation of the indicated synthetic H3 peptides in the presence of
S-adenosyl-L-[methyl-3H]methionine, and incorporated radioactivity
was determined by filter binding. The GST pull-down experiments
were done as previously described (17, 19) with GST fusions to the
N-terminal 57 residues of human H3 (wild type [wt]) and point mu-
tants, and 20% of the total reaction mixture was loaded as input.
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(Fig. 7C, right panel). It is interesting that H3-K4 methylation,
at least with these retinoid-responsive promoter regions, could
be far more dynamic than was previously hypothesized (29).
Thus, transactivation by nuclear receptors in vivo may require
recruitment of ASCOM to target DNA response elements via
the ligand-dependent interactions of ASC-2 and receptors,
which may lead to subsequent, transient methylation of H3-K4
residues of the promoter region.
Interestingly, cotransfections of HR/SET1 inhibited transac-
tivation by various nuclear receptors, including RAR (Fig. 8A
and data not shown). Two possibilities exist. First, HR/SET1
may block the interactions of HALR/ALR-1/2 and their down-
stream effectors. Second, HR/SET1 may interfere with the
endogenous HALR/ALR-1/2 from properly methylating their
putative target substrates in vivo (H3 and/or other yet un-
known substrates). Consistent with the latter possibility, mu-
tation of a highly conserved glycine residue into serine (i.e.,
HR/SET1m1) or deletion of the conserved NHSC motif (i.e.,
HR/SET1) abolished the repression (Fig. 8A). The point-
mutation was based on the previously described Drosophila
trxZ11 mutation that lacks H3 binding and causes homeotic
transformation in the fly (13). Interestingly, the H3 binding was
also impaired with HR/SET1, suggesting the involvement of
the NHSC motif in H3 bindings (Fig. 8B).
Overall, these results demonstrate that ASC-2 functions as a
whole complex (i.e., ASCOM), and H3 binding by ASCOM
and recruitment of ASCOM to target DNA response elements
via the ASC-2-receptor interactions appear to be essential for
transactivation by nuclear receptors in vivo.
DISCUSSION
ASC-2 is a steady-state complex homologous to the ySET1
complex. In this report, we have described a novel nuclear
steady-state complex of approximately 2 MDa from HeLa nu-
clei, which is associated with the previously described tran-
scriptional coactivator molecule ASC-2 (3, 8, 14, 17, 18, 19, 22,
52). ASCOM likely represents a human orthologue of a re-
cently reported yeast complex of approximately 440 to 1,000
kDa (25, 26, 35), which contains ySET1, yASH2, three proteins
with the WD repeats (reviewed in reference 21) that are also
found in RBQ-3, and a subunit called Cps40/Saf41p/Spp1, a
homologue of hCGBP that recognizes unmethylated CpG is-
lands and contains conserved cysteine-rich motifs found in
hTrx/MLL and the N-terminal region of ALR-1 (44). They
further demonstrated that ySET1 is an H3-K4 methylase (26,
35). However, ASC-2 homologues do not seem to exist in
Saccharomyces cerevisiae, Caenorhabditiselegans, and Drosoph-
ila (data not shown), suggesting the incorporation of ASC-2
into the complex relatively later in evolution. Notably, ASH2,
ALR-1, ALR-2, and HALR as well as the yeast counterparts
ySET1 and yASH2 are homologues of the known members of
FIG. 7. Recruitment of ASCOM in RAR transactivation. (A) The
retinoid-responsive -RARE-LUC reporter construct was cotrans-
fected into HeLa cells, along with lacZ expression vector (100 ng) and
expression vectors for DN1 (100 ng) or DN1/m (100 ng). Closed and
shaded boxes indicate the absence and presence of 0.1 M 9-cis-
retinoic acid (RA), respectively. Normalized luciferase expressions
from triplicate samples were calculated relative to the lacZ expres-
sions. Similar results were obtained with CV-1 cells (data not shown).
(B and C) ASCOM recruitment to -RARE and p21WAF1 and H3-K4
methylation. 293T cells were cotransfected with expression vectors for
RAR (10 ng), DN1 (100 ng), and DN1/m (100 ng) either in the absence
or in the presence of 0.1 M 9-cis-RA, as indicated. Chromatin from
these cells was isolated and immunoprecipitated with the indicated
antibodies. The endogenous -RARE or p21WAF1 region present in
the immunoprecipitated samples was amplified by PCR, and input
PCR is shown for the loading controls.
FIG. 8. Inhibition of RAR transactivation by HALR-SET. (A) The
retinoid-responsive -RARE-LUC reporter construct was cotrans-
fected into HeLa cells, along with the lacZ expression vector (100 ng)
and expression vectors for HR/SET1, HR/SET1m1, and HR/SET1,
as indicated. Closed and shaded boxes indicate the absence and pres-
ence of 0.1 M of 9-cis-retinoic acid (RA), respectively. Normalized
luciferase expressions from triplicate samples were calculated relative
to that of the lacZ expressions. Similar results were obtained with
CV-1 cells (data not shown). (B) GST pull-down experiments were
done as previously described (17, 19) with GST alone or a GST fusion
to the N-terminal 57 residues of human H3, and 20% of the total
reaction mixture was loaded as input.
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the Drosophila Trx-G proteins (7). Thus, ASCOM and the
ySET1 complex represent a distinct coactivator complex that
contains a subset of defined Trx-G proteins, along with the
ATPase-dependent chromatin remodeling Swi/Snf complex (7,
9) and the recently reported dTrx/dCBP complex (31). Nota-
bly, three components (i.e., ALR-1, ALR-2, and HALR) are
relatively large in size (Fig. 1B), which has significantly blunted
our effort to map the intrainteraction interfaces among various
different components. From our recent yeast two-hybrid
screening, however, ASH2 was isolated as a protein that
strongly interacts with RBQ-3. Thus, ASH2–RBQ-3 may form
a core submodule loosely attached to ASCOM or the puta-
tively independent complex of approximately 500 kDa (Fig.
3A).
DN1 as a specific inhibitor of ASC-2 in vivo. The ASC-2
fragment DN1, which interacts with RAR in an LXXLL-de-
pendent manner, acted as a potent dominant-negative inhibi-
tor of the RAR transactivation (Fig. 7A). Importantly, this
DN1-mediated repression was recovered by overexpressed
ASC-2 but not by SRC-1 or TRAP220, two well-characterized
LXXLL-type coactivators (13a). In ChIP experiments with cul-
tured cell lines, DN1 also inhibited the retinoid-dependent
recruitment of ASC-2, but not of TRAP220 and SRC-1, to the
retinoid-responsive p21WAF1 promoter (Fig. 7B). Further-
more, ChIP analyses of mouse embryo fibroblasts from trans-
genic mice overexpressing DN1, which exhibit various pheno-
types derived from the compromised retinoid and other ligand
signalings, indicated that the ligand-dependent recruitment of
ASC-2 to the RAR2 promoter was impaired, whereas the
recruitment of TRAP220 was unaffected (13a). Similarly, mi-
croinjection of anti-ASC-2 antibody was shown to repress the
RAR transactivation, which was recovered by coinjected ex-
pression vector for ASC-2, but not SRC-1 or CBP (17). How-
ever, it’s important to note that DN1 can compete with recom-
binant TRAP220 and SRC-1 to bind receptors in vitro (data
not shown). This discrepancy attests to the important fact that
ASC-2, TRAP220, and SRC-1 exist within distinct steady-state
complexes in vivo but not as free polypeptides, as used in our
in vitro experiments. Within the context of complex, the addi-
tional ASC-2 sequences present in DN1 may serve as an inter-
action interface with other effectors required for the successful
recruitment of ASCOM. The LXXLL motif-mediated interac-
tions of ASC-2 with receptors may have to accompany these
secondary interactions for a successful assembly of the whole
ASCOM-receptor complex on the promoter region. Further-
more, it should be noted that the interactions of receptors with
various cofactors are highly dynamic, not static, as recently
demonstrated with estrogen and androgen receptors (37, 38).
Although more work is needed to clearly understand the basis
for this specificity, our results are sufficient to demonstrate that
DN1 is an excellent tool to study the function of the endoge-
nous ASC-2 complex with nuclear receptors in vivo, without
any complication from other LXXLL-based coactivators such
as SRC-1 and TRAP220. Thus, we concluded that the ligand-
induced transient methylation of H3-K4 residues around the
RAR2 and p21WAF1 promoter regions (Fig. 7C), which was
abolished by coexpressed DN1, but not by DN1/m, may have
resulted from the H3-K4 methylation activities of ASCOM,
although the possible involvement of or communication with
other histone methylase(s) could not be excluded.
ASCOM and H3-K4 methylation. H3-K4 methylation has
been intrinsically linked to gene activation (29, 39). Recently,
H3-K4 methylation mediated by a novel protein, SET9, was
demonstrated to enhance histone acetylation by p300 and sup-
press the transcriptionally repressive SUV39 h1-mediated
H3-K9 methylation as well as the binding of the NuRD repres-
sor complex to the H3 tail (28, 46). Interestingly, the HALR-
mediated H3 methylation activity in vitro was very weak rela-
tive to other histone methyltransferases (28, 33, 42, 46). In
addition, the activity was not significantly affected by H3-S10
phosphorylation or H3-K14 acetylation, and almost nondetect-
able with mononucleosomes (data not shown). Thus, HALR/
ALR may require other cofactors lost during the purification
or function in a promoter-specific manner. For instance, the
ySET1 complex required other components in addition to the
enzymatic component itself (i.e., ySET1) for successful meth-
ylation activities (35). Thus, a series of stable cell lines that
express Flag-tagged ASC-2, ASH2, and RBQ-3 are currently
being developed, from which we plan to purify a functionally
intact complex. In addition, it was recently demonstrated that
methylation of H3-K4 by the ySET1 complex requires ubiq-
uitination of H2B by RAD6 (6, 41). Thus, the weak in vitro
methylase activity of ASCOM may also stem from the lack of
ubiquitinated H2B under the reaction conditions we employed.
Finally, HALR/ALR may also target nonhistone proteins, such
as other coactivators, as recently documented for the H3-spe-
cific arginine methyltransferase CARM1 that methylates CBP/
p300 (51). To clearly resolve these issues, we are currently
constructing gene-targeted mice in which the methylase activ-
ity of HALR is specifically altered.
ASCOM and other coactivator complexes. As schematically
indicated in Fig. 9, unliganded nuclear receptors recruit core-
pressor proteins N-CoR and SMRT, which complex with var-
ious histone deacetylase enzymes that inhibit transcription (9).
One primary step toward gene activation is believed to be the
recruitment of proteins that disrupt chromatin formation. Co-
regulators equivalent to factors of the yeast Swi/Snf complex,
such as BRG1, and related complexes regulate chromatin re-
modeling. In addition, ligand-dependent recruitment of SRC-
1/CBP/p/CAF complexes brings HAT activity to nuclear recep-
tor complexes (Fig. 9). Furthermore, biochemically isolated
complexes that contain factors similar or homologous to fac-
tors in the yeast mediator complex (i.e., TRAP-SMCC-DRIP-
ARC) have been isolated by coprecipitation of different tran-
scription factors, which might be involved in directly bridging
the RNA polymerase II complex with basal transcription fac-
tors (9). ASCOM is the fourth kind of nuclear receptor coac-
tivator complex, which might be involved with methylating
H3-K4 residues of the target promoter regions (Fig. 9). Nu-
clear receptor-mediated transactivation requires these and
other coactivator complexes that can act sequentially, combi-
natorially, or in parallel. The selective recruitment of coacti-
vators by individual receptors has been well established (47,
48). These selective receptor-coactivator interactions represent
an efficient system through which the pleiotropic effects of
nuclear receptor ligands might be mediated and are likely
further determined by tissue-specific patterns of posttransla-
tional modification of coactivators (15). In this regard, two
issues will be particularly relevant for further studies of AS-
COM. It will be important to examine how ASCOM is func-
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tionally interrelated to other coactivators during the transacti-
vation processes. For instance, our preliminary results indicate
that ASCOM may functionally require the intact Swi/Snf com-
plex in vivo. Furthermore, HR/SET1, the C-terminal fragment
of HALR, appears to modulate the H3 arginine methylase
activities of CARM1 at least in vitro, another pivotal coacti-
vator protein of nuclear receptors. Another equally important
question will be to determine whether ASCOM can be selec-
tively utilized under different contexts and conditions in vivo,
i.e., what are the major physiological target genes of ASCOM?
Nuclear tubulins in ASCOM. This report extends the pre-
vious intriguing reports of the presence of tubulin proteins in
the nucleus (24, 45). The copurification of /-tubulins with
the other ASCOM components HALR, ASC-2, ASH2, and
RBQ-3 (Fig. 3A) from the highly purified Superose 6 fractions
that lack the abundant cellular free tubulins as well as the
coimmunoprecipitation with ASH2 in these fractions (Fig. 3B)
strongly support the authenticity of /-tubulins as true com-
ponents of ASCOM. The indirect immunofluorescence results
(Fig. 3D) also support this notion. Given the presence of /-
tubulins in ASCOM, one interesting hypothesis to test will be
whether the nuclear matrix (5) can modulate the function of
ASCOM. Our preliminary results indicate that the previously
defined autonomous transactivation function of ASC-2 (19, 22)
is strongly induced by the tubulin-destabilizing agent vinblastin
but not by the tubulin-stabilizing agent taxol (our unpublished
results). Interestingly, it was previously noted that vinblastin
affects biochemical processes that are seemingly unrelated to
tubulin, such as DNA and RNA synthesis (2). It is possible that
the effects of vinblastin on these processes could occur through
an interaction with the nuclear tubulins present in ASCOM.
The biological significance of the presence of /-tubulins in
ASCOM will be an exciting future investigation.
ASCOM and human cancer. It is noted that mutations
and/or translocations into the trx/mll gene in mammals result in
the development of several types of hematological malignan-
cies (1). The ALR and HALR genes map to chromosome
bands 12q12-13 and 7q36, respectively, regions associated with
chromosomal aberrations encountered in human cancers (32,
43). RBQ-3 was also reported to be gene amplified in certain
gliomas (36), like the ASC-2 gene in colon, breast, and lung
cancers (17). Interestingly, -tubulin was recently shown to
accumulate in rapidly dividing cells, such as cancer cell lines
and tissues (45). These results suggest that misregulation of
different ASCOM subunits might be linked to carcinogenesis.
In conclusion, ASC-2, essential for transactivation by nu-
clear receptors and likely many other transcription factors, is a
component of a novel human Trx-G complex capable of spe-
cifically methylating H3-K4. Further characterization of AS-
COM will facilitate the unraveling of the molecular details of
transcriptional control as well as cancer development.
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